Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., February 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NTLA) - a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, announced that on February 1, 2026, it awarded inducement grants to six new employees under Intellia’s 2024 Inducement Plan as a material inducement . . . This content is for …
Bio-Techne Corp Q2 Financial Results Yesterday, February 4, 2026 /PRNewswire/ -- Bio-Techne Corporation (TECH) reported its financial results for the second quarter ending December 31, 2025. Second Quarter FY2026 Highlights Second quarter revenue . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Intellia Therapeutics News January 27, 2026, Intellia Therapeutics, Inc. (NTLA), today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on the Investigational New Drug application (IND) for the MAGNITUDE-2 Phase 3 clinical trial of nexiguran ziclumeran (nex-z) for patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv . . . This content is for paid subscribers. Please click here to subscribe …
BioCryst Pharmaceuticals Acquires Astria Pharmaceuticals Today, January 23, 2026, BioCryst Pharmaceuticals, Inc. (BCRX) announced it completed acquisition of Astria Therapeutics, Inc., initially announced on October 14, 2025. The transaction strengthens its position as a leader in hereditary angioedema (HAE) and enhances the company’s long-term growth trajectory. BioCryst adds navenibart BioCryst, a late-stage, long . . . This content is for paid subscribers. Please click here to …
Corcept Therapeutics Yesterday, January 22, 2026, Corcept Therapeutics (CORT) - a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that ROSELLA, the company’s pivotal Phase 3 trial of relacorilant plus nab-paclitaxel to treat patients with platinum-resistant . . . This content is for paid subscribers. Please …
Bristol-Myers Squibb and Microsoft Collaboration Bristol-Myers Squibb (BMY) - a global leader in oncology, announced an agreement with Microsoft, a market leader in AI-powered radiology and clinical workflow technologies, aiming to accelerate early detection of lung cancer. Through this digital health collaboration, U.S. FDA-cleared radiology AI algorithms will be deployed via Microsoft’s Precision Imaging Network . . . This content is for paid subscribers. Please click here …
GSK Agreement to Acquire RAPT Therapeutics Yesterday, January 20, GSK (GSK) announced that it has entered a definitive agreement to acquire RAPT Therapeutics (RAPT) a California-based, clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Sanofi's Myqorzo & Redemplo Paris, January 15, 2026, the National Medical Products Administration in China has approved two Sanofi-licensed innovative medicines, Myqorzo (aficamten) for the treatment of obstructive hypertrophic cardiomyopathy (oHCM), and Redemplo (plozasiran) for the reduction of triglyceride levels in adult patients with familial chylomicronaemia syndrome (FCS) on the basis of dietary control. From Sanofi Olivier Charmeil, Executive Vice President, General Medicines, Sanofi, Said, “We …
Eli Lilly The FDA extended its review for Eli Lilly (LLY) oral obesity drug, orforglipron, pushing the target decision date to April 10, 2026, from earlier expectations of late March, despite it receiving a Commissioner's National Priority Voucher for faster . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Sentynl Therapeutics JANUARY 13, 2026, Sentynl Therapeutics – a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences Limited (“Zydus Group”), announced that the U.S. FDA has approved ZYCUBO® (copper histidinate) for the treatment of Menkes disease in pediatric patients. This is the first and only treatment approved for Menkes disease, a rare and fatal genetic condition, in the United States. ZYCUBO® is not indicated for the treatment of …
Anavex Life Sciences Corp Today, January 13, 2026, Anavex Life Sciences Corp. (AVXL) announced its participation as a key industry partner in ACCESS-AD, a major new European initiative designed to accelerate the adoption of innovative diagnostic and therapeutic approaches for Alzheimer’s disease (AD) across real‑world clinical settings. The multi-year program is funded by the . . . This content is for paid subscribers. Please click here …
AbbVie and RemeGen Announce Licensing Agreement Today, January 12, 2026, - AbbVie (ABBV) and RemeGen announced an exclusive licensing agreement for the development, manufacturing and commercialization of RC148, a novel investigational Programmed Cell Death-1 (PD-1)/Vascular Endothelial Growth Factor (VEGF)-targeted bispecific antibody. RC148 is currently being developed by RemeGen as a monotherapy . . . This content is for paid subscribers. Please click here to subscribe or …
Insmed Inc Insmed Inc is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. Insmed is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory …
Rapport Therapeutics in the NEWS Today, January 07, 2026, Rapport Therapeutics, Inc. (RAPP) announced plans to initiate its Phase 3 program for RAP-219 in FOS in the second quarter of 2026 and expand its epilepsy portfolio with a new program in PGTCS. Additionally, the Company announced progress across its pipeline, including . . . This content is for paid subscribers. Please click here to subscribe or …
Incyte in the NEWS January 5, 2026 - Incyte (INCY) announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for . . . This content is for paid …
Vanda Pharmaceuticals During December 2025, Vanda Pharmaceuticals Inc. (VNDA) announced that the U.S. Food and Drug Administration (FDA) has approved NEREUS™ (tradipitant), an oral neurokinin-1 (NK-1) receptor antagonist, for the prevention of vomiting induced by motion. This approval marks the first new pharmacologic treatment in motion sickness in over four decades, representing a significant advancement . . . This content is for paid subscribers. Please …
Happy New Year 2026 Following the celebrations of Faiths, we wish you all that you believe is best for you, your family and friends. May God bless you and protect you, your children and parents. We are optimistic for 2026 and for U.S. citizens. Our optimism is based on great news about the United States' economy, which is ending 2025 strongly with a growing GDP, …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
